238 related articles for article (PubMed ID: 35668119)
1. Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2.
Fang Z; Peng L; Filler R; Suzuki K; McNamara A; Lin Q; Renauer PA; Yang L; Menasche B; Sanchez A; Ren P; Xiong Q; Strine M; Clark P; Lin C; Ko AI; Grubaugh ND; Wilen CB; Chen S
Nat Commun; 2022 Jun; 13(1):3250. PubMed ID: 35668119
[TBL] [Abstract][Full Text] [Related]
2. Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2.
Fang Z; Peng L; Filler R; Suzuki K; McNamara A; Lin Q; Renauer PA; Yang L; Menasche B; Sanchez A; Ren P; Xiong Q; Strine M; Clark P; Lin C; Ko AI; Grubaugh ND; Wilen CB; Chen S
bioRxiv; 2022 Feb; ():. PubMed ID: 35194606
[TBL] [Abstract][Full Text] [Related]
3. Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.
Valanparambil RM; Carlisle J; Linderman SL; Akthar A; Millett RL; Lai L; Chang A; McCook-Veal AA; Switchenko J; Nasti TH; Saini M; Wieland A; Manning KE; Ellis M; Moore KM; Foster SL; Floyd K; Davis-Gardner ME; Edara VV; Patel M; Steur C; Nooka AK; Green F; Johns MA; O'Brein F; Shanmugasundaram U; Zarnitsyna VI; Ahmed H; Nyhoff LE; Mantus G; Garett M; Edupuganti S; Behra M; Antia R; Wrammert J; Suthar MS; Dhodapkar MV; Ramalingam S; Ahmed R
J Clin Oncol; 2022 Nov; 40(33):3808-3816. PubMed ID: 35759727
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.
Zang J; Yin Y; Xu S; Qiao W; Liu Q; Lavillette D; Zhang C; Wang H; Huang Z
Front Immunol; 2022; 13():908478. PubMed ID: 35844601
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice.
Kim E; Khan MS; Ferrari A; Huang S; Sammartino JC; Percivalle E; Kenniston TW; Cassaniti I; Baldanti F; Gambotto A
Microbiol Spectr; 2023 Jun; 11(3):e0436322. PubMed ID: 37162333
[TBL] [Abstract][Full Text] [Related]
7. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant.
Zuo F; Abolhassani H; Du L; Piralla A; Bertoglio F; de Campos-Mata L; Wan H; Schubert M; Cassaniti I; Wang Y; Sammartino JC; Sun R; Vlachiotis S; Bergami F; Kumagai-Braesch M; Andréll J; Zhang Z; Xue Y; Wenzel EV; Calzolai L; Varani L; Rezaei N; Chavoshzadeh Z; Baldanti F; Hust M; Hammarström L; Marcotte H; Pan-Hammarström Q
Nat Commun; 2022 May; 13(1):2670. PubMed ID: 35562366
[TBL] [Abstract][Full Text] [Related]
8. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost.
Ai J; Zhang H; Zhang Y; Lin K; Zhang Y; Wu J; Wan Y; Huang Y; Song J; Fu Z; Wang H; Guo J; Jiang N; Fan M; Zhou Y; Zhao Y; Zhang Q; Liu Q; Lv J; Li P; Qiu C; Zhang W
Emerg Microbes Infect; 2022 Dec; 11(1):337-343. PubMed ID: 34935594
[No Abstract] [Full Text] [Related]
9. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination.
Pérez-Then E; Lucas C; Monteiro VS; Miric M; Brache V; Cochon L; Vogels CBF; Malik AA; De la Cruz E; Jorge A; De Los Santos M; Leon P; Breban MI; Billig K; Yildirim I; Pearson C; Downing R; Gagnon E; Muyombwe A; Razeq J; Campbell M; Ko AI; Omer SB; Grubaugh ND; Vermund SH; Iwasaki A
Nat Med; 2022 Mar; 28(3):481-485. PubMed ID: 35051990
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing Activity Against SARS-CoV-2 Delta and Omicron Variants Following a Third BNT162b2 Booster Dose According to Three Homologous or Heterologous COVID-19 Vaccination Schedules.
Choi JY; Lee YJ; Ko JH; Kim SH; Kim HJ; Lee HW; Jeong H; Kim TY; Jang YG; Hong HJ; Kim MS; Lee SE; Kim YG; Chung EJ; Lim H; Jang S; Kim K; Kim SS; Ahn JY; Choi JY; Kim YC; Park YS; Peck KR; Kim B
Front Cell Infect Microbiol; 2022; 12():948014. PubMed ID: 35899050
[TBL] [Abstract][Full Text] [Related]
11. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
[TBL] [Abstract][Full Text] [Related]
12. Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination.
Suntronwong N; Kanokudom S; Auphimai C; Assawakosri S; Thongmee T; Vichaiwattana P; Duangchinda T; Chantima W; Pakchotanon P; Chansaenroj J; Puenpa J; Nilyanimit P; Srimuan D; Thatsanatorn T; Sudhinaraset N; Wanlapakorn N; Mongkolsapaya J; Poovorawan Y
J Med Virol; 2022 Dec; 94(12):5713-5722. PubMed ID: 35924475
[TBL] [Abstract][Full Text] [Related]
13. Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination.
Assawakosri S; Kanokudom S; Chansaenroj J; Suntronwong N; Auphimai C; Nilyanimit P; Vichaiwattana P; Thongmee T; Duangchinda T; Chantima W; Pakchotanon P; Srimuan D; Thatsanatorn T; Klinfueng S; Sudhinaraset N; Mongkolsapaya J; Wanlapakorn N; Honsawek S; Poovorawan Y
Int J Infect Dis; 2022 Sep; 122():793-801. PubMed ID: 35863731
[TBL] [Abstract][Full Text] [Related]
14. Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects.
Haveri A; Solastie A; Ekström N; Österlund P; Nohynek H; Nieminen T; Palmu AA; Melin M
Eur J Immunol; 2022 May; 52(5):816-824. PubMed ID: 35312186
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model.
Ji Y; Sui X; Miao W; Wang C; Wang Q; Duan Z; Wei B; Wu D; Wei M; Shao J; Zheng X; Zhu T
Vaccine; 2024 Feb; 42(6):1292-1299. PubMed ID: 38296705
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
[TBL] [Abstract][Full Text] [Related]
17. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
Elife; 2022 Aug; 11():. PubMed ID: 36004719
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection.
Evans JP; Zeng C; Carlin C; Lozanski G; Saif LJ; Oltz EM; Gumina RJ; Liu SL
Sci Transl Med; 2022 Mar; 14(637):eabn8057. PubMed ID: 35166573
[TBL] [Abstract][Full Text] [Related]
19. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies.
Wang X; Zhao X; Song J; Wu J; Zhu Y; Li M; Cui Y; Chen Y; Yang L; Liu J; Zhu H; Jiang S; Wang P
Emerg Microbes Infect; 2022 Dec; 11(1):477-481. PubMed ID: 35034583
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
